Hormone Therapy for Breast Cancer

Hormone therapy for breast cancer is a treatment designed to slow cancer growth or reduce the risk of recurrence by decreasing the effects of oestrogen, and in some cases progesterone, in hormone receptor-positive tumours. It is not used in every type of breast cancer; the decision depends on the biological characteristics of the tumour and the stage of disease. ^[1][2][3]

What does hormone therapy mean in breast cancer?

In breast cancer, hormone therapy is also commonly referred to as endocrine therapy. The logic behind it is that some breast cancer cells use oestrogen or progesterone signals to grow. If the tumour is hormone receptor-positive, drugs that block the effect of these hormones or reduce hormone levels in the body may become part of the treatment plan. In other words, the goal is not to treat cancer by “giving hormones,” but by blocking hormonal stimulation. ^[1][2][5]

This treatment does not work in every breast cancer. Whether hormone therapy is appropriate is determined by examining biomarkers such as oestrogen receptor and progesterone receptor in the tumour sample. Endocrine therapy has no role in hormone receptor-negative cancers. For that reason, detailed review of the pathology report after diagnosis is fundamental to treatment planning. ^[1][2][4]

Who receives it?

Hormone therapy is used most commonly after surgery in hormone receptor-positive early-stage breast cancer to reduce the risk of recurrence. In some situations, it may also be planned before surgery to help shrink the tumour. In advanced or metastatic disease, it may be used to slow tumour growth, control symptoms, and contribute to survival and quality of life. ^[1][2][3]

The type of treatment chosen varies according to menopausal status, tumour stage, lymph node involvement, previous treatments, and coexisting medical conditions. For example, the drug classes used in premenopausal and postmenopausal patients are not always the same. That is why two patients with what appears to be the same diagnosis may still receive different hormone therapy plans. ^[1][2][4]

Which medications are used?

The most common approaches in hormone therapy for breast cancer include selective oestrogen receptor modulators, aromatase inhibitors, and, in some cases, other drugs targeting the oestrogen receptor pathway. Tamoxifen is one of the classic and long-established options. Aromatase inhibitors work by reducing oestrogen production in the body and are especially important in the postmenopausal setting. ^[1][2][3]

In advanced disease, some targeted treatments may be combined with hormone therapy. This is particularly relevant in metastatic hormone receptor-positive, HER2-negative breast cancer. Even so, drug selection depends on tumour biology, prior therapies, and the patient’s side-effect profile. Seeing the name of a medication online does not mean it is appropriate for everyone. ^[2][3][5]

How long does treatment last?

The duration of hormone therapy depends on the stage of disease and the aim of treatment. In early-stage breast cancer, plans lasting for years may be considered; some patients are treated for 5 years, whereas longer durations may be appropriate in others. In metastatic disease, treatment may continue as long as it remains effective and tolerable. For that reason, duration is less a fixed number than a matter of individualized risk assessment. ^[1][2][3]

When long-term use is planned, regular follow-up and adherence become especially important. Although endocrine therapy may look like a simple daily medication, it is in fact a crucial step that can influence the risk of cancer recurrence. If side effects create a temptation to stop treatment, this should be discussed with the oncology team, because there are often management options. ^[1][2][3]

Side effects and quality of life

Side effects vary according to the drug used. Hot flushes, sweating, joint pain, vaginal dryness, mood changes, fatigue, and problems affecting sexual life are among the most commonly reported complaints. Some medicines may require monitoring related to bone health, clotting risk, or the lining of the uterus. For that reason, side-effect management should be considered a natural part of treatment. ^[1][2][3]

Experiencing side effects does not mean the treatment has failed, but silently accepting them without discussion is not the right approach either. Options such as exercise, bone-health monitoring, support for menopausal symptoms, and sometimes switching medications may be considered. Preserving quality of life while continuing treatment is an important goal in oncology. ^[1][2][5]

Is hormone therapy the same as chemotherapy?

No. Hormone therapy and chemotherapy work through different mechanisms. Chemotherapy involves broader cytotoxic drugs, whereas hormone therapy is effective only in cancers that depend on hormonal signalling. For that reason, some patients may receive both treatments either sequentially or together, while in others hormone therapy alone may be sufficient. ^[1][2][3]

Likewise, targeted therapy and immunotherapy are different from hormone therapy. Modern breast cancer treatment is layered according to tumour biology. One of the questions patients often find confusing is whether being “hormone positive” is good or bad. The answer is not simple, but hormone receptor status is an important piece of information that can expand treatment options. ^[2][4][5]

What is monitored during follow-up?

In patients receiving hormone therapy, regular oncology visits, side-effect monitoring, and additional evaluations such as bone-density testing when needed are important. Because menopausal status may change over time, some treatment plans may need to be updated. New pain, unexplained weight loss, shortness of breath, or persistent side effects should always be mentioned during follow-up visits. ^[1][2][3]

The use of other medicines, interest in herbal products, or pregnancy planning should also be discussed during follow-up. Fertility and pregnancy plans are especially important in patients of reproductive age. Decisions about pausing or stopping treatment should never be based solely on internet advice, but on discussion with the oncology team. ^[2][3][5]

When should you contact a doctor?

During hormone therapy, unusual vaginal bleeding, sudden swelling or pain in the leg, shortness of breath, severe joint complaints, marked depressive symptoms, or side effects that interfere with daily life should prompt contact with the healthcare team. Difficulty taking the medication regularly is also an important follow-up issue and should not be glossed over. ^[1][2][3]

Hormone therapy for breast cancer is a highly valuable treatment step in the right patient. However, suitability, duration, and drug selection are entirely based on individualized assessment. The safest approach is to make shared decisions with the oncology team in light of the pathology results and the clinical picture. ^[1][2][4]